Gastric inhibitory peptide receptor (GIPR) (GIPR)

The Gastric inhibitory peptide receptor (GIPR) is a member of the class B G protein-coupled receptor family, primarily expressed in pancreatic beta cells, adipose tissue, and the central nervous system (UniProt: P48546). Its primary endogenous ligand is gastric inhibitory peptide, also known as glucose-dependent insulinotropic polypeptide, which is secreted by intestinal K-cells in response to nutrient ingestion (PubMed: 16416334). Upon activation, GIPR stimulates insulin secretion in a glucose-dependent manner, contributing significantly to the incretin effect and postprandial glucose regulation (StatPearls: NBK546669). Beyond glycemic control, GIPR signaling is involved in lipid metabolism, bone remodeling, and neuroprotection, making it a versatile therapeutic target (PubMed: 33161031). In clinical practice, GIPR has become a cornerstone for treating type 2 diabetes and obesity, particularly through dual or triple agonists like tirzepatide that combine GIPR activation with GLP-1 receptor stimulation (PubMed: 34170647). These multi-receptor therapies have demonstrated superior efficacy in weight reduction and glycemic management compared to traditional treatments. Interestingly, both GIPR agonism and antagonism are being explored for metabolic benefits, with some evidence suggesting that GIPR inhibition may also promote weight loss in specific contexts (PubMed: 33161031). The receptor's role in the brain is increasingly recognized as a key mediator of the weight-lowering effects of multi-incretin drugs. Safety profiles for GIPR-targeting drugs generally involve manageable gastrointestinal side effects, though long-term monitoring for pancreatitis remains standard. Overall, GIPR represents a high-value target in the rapidly evolving landscape of metabolic medicine.

Other names

Glucose-dependent insulinotropic polypeptide receptorGIP receptorGIP-R

Agonism of the GIPR stimulates adenylate cyclase, increasing intracellular cAMP levels and leading to glucose-dependent insulin secretion from pancreatic beta cells (PubMed: 16416334). In the central nervous system, GIPR signaling modulates appetite and energy expenditure, while in adipose tissue, it influences lipid storage and insulin sensitivity (PubMed: 33161031).